

ADVERTISEMENT



Chayse is a promotional speaker compensated by Sanofi.

Sign up for the ALTUVIII[®] Peer Mentor Program

Connect with real ALTUVIII[®] patients and caregivers for advice, information about their experience, and more

Sign up today!

ALTUVIII[®]
Antihemophilic factor (Recombinant), Fc-vWF-ADTN Fusion Protein-vWF

MAT-US-2502927-v1.0-04/2025



COMMUNIQUE

For Bleeding Disorders

OCTOBER 2026

Welcome

The world seems closer to our doorsteps thanks to social media. In the 1990s, it took letter writing to reach patients in need in developing countries; now we have instantaneous access. This creates great benefits for patients in need, but can also create problems for American patients and families who want to help. While we all want to help patients in need, the best course of action is to contact experts in overseas humanitarian relief, like Save One Life, the World Federation of Hemophilia... or us!

We had such a huge amount of factor donated this summer, I had to post it first in our Communiqué this month. Thanks to all who donated!

Stay safe and hopeful,

Laurie



World

Record-breaking Donations of Factor

We received an astounding, record-breaking 2,679,626 IU of factor and 17,154 milligrams of inhibitor medication in the third quarter. Rather than destroy it, this unwanted medication was donated

by patients, specialty pharmacies and HTC's. In turn, we shipped this to 13 developing countries, to patients, nonprofits and HTC's, at no cost to recipients. The value in total this quarter is in the tens of millions of dollars, donated to patients who would otherwise not receive it from their governments or be able to purchase it. Thanks to all our donors!



Events

Webinar Wednesdays

Each Wednesday, the National Bleeding Disorder Foundation presents a series of free educational hour-long webinars with moderated Q&A to bring knowledge about the latest in research, breakthrough developments, and more to the bleeding and blood disorders community. October 28, November 4, 2026, 2:00 PM EST. [Register here.](#)



B at the Symposium!

The Coalition for Hemophilia B will hold its 2027 Symposium at the Renaissance Orlando at SeaWorld. This symposium gathers patients with hemophilia B, their families, healthcare providers and advocacy leaders to share and learn. Priority travel grants given to first-time attendees and driving grant applications. March 18–21, 2027. [Register here.](#)



Resources

My First Factor Song


Sing along and teach through song! To the tune of "Alouette," teach your toddler with hemophilia about bumps, bruises, "boo-boos," factor. Lyrics by hemophilia mom Carri Nease. [Download in MP3 format for free.](#)



Hemophilia in Pictures


This color-illustrated guide to hemophilia is the

perfect educational tool for parents, nurses and other healthcare providers, and anyone seeking to transmit basic information about hemophilia and its management. Available in [English](#), [Spanish](#), [French](#), [Arabic](#), [Russian](#), and more. [Download here](#).



B2B Book Series Young Adults & Hemophilia B

Get information about dating, moving out, starting a career, and starting a family in this book written for young adults. Sponsored by Pfizer. [Download here](#).



WFH Treatment Guidelines Resource Hub

This centralized online platform gives healthcare professionals, researchers, people with bleeding disorders, and the wider community a streamlined way to access the latest evidence-based guidance for care. The Resource Hub brings together the WFH Guidelines for the Management of Hemophilia and the ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis and Management of von Willebrand Disease in one location. Visit: [click here](#).



Medical

Artificial Intelligence and Hemophilia

Hemophilia News Today shares an article in which AI shows promise for helping doctors diagnose hemophilia, detect joint complications, and predict disease severity and other clinical outcomes. “Artificial Intelligence and Machine Learning in the Context of Hemophilia: A Scope Review,” published in *Haemophilia*, also reports barriers to routine clinical implementation. [Read more here](#).

Science

Mim8 on the Horizon

Frehemgo (generic name denecimig, originally known as Mim8) is a next-generation medication developed by Novo Nordisk for routine prophylaxis of bleeding episodes in adults and children with hemophilia A. It is a bispecific antibody that acts as a factor VIIIa mimetic by mimicking the function of

missing factor VIII, bridging factor IXa and factor X to help the blood clot naturally. It's designed for patients with or without factor VIII inhibitors. It stands out as the first treatment of its kind to offer multiple subcutaneous dosing frequencies—once-weekly, once every two weeks, or once-monthly—administered via a single-use, pre-filled disposable pen. For more info: contact your hemophilia treatment center.

Advocacy

What to Learn about Advocacy?

The HIV scandal of the 1990s created fierce and exemplary advocacy strength in the bleeding disorders community. Our advocates championed successful compensation for families, and a safer national blood supply. The community continues to need advocates to safeguard our treatment and access to treatment in these turbulent times. If you want to learn advocacy from the experts, reach out to Hemophilia Federation of America for starters. Their Advocacy Hub is a great place to start to learn how to shape policy and change our futures for the better.

[Learn more here.](#)




HemaBlog

Badwater Bravo

“Badwater 135” is a documentary about the Mount to Coast Badwater® 135, a 135-mile non-stop ultramarathon known as the world’s toughest foot race. It takes place in Death Valley—one of the hottest places on earth. The movie profiles several runners, how they trained and why they run. One of them is Ricardo Ramirez, who competed and completed Badwater 135 in 2022, representing Mexico. He is the first person with hemophilia to finish the world’s toughest foot race.

[Read more here.](#)



In Case You Haven't Heard...

- When reporting the number of people affected by bleeding disorders, it is

important to understand the distinction between incidence and prevalence.

- Incidence refers to the number of new cases of a disorder that occur in a specific population during a defined period of time. In other words, it measures how frequently new cases arise.
- Prevalence refers to the total number of existing cases of a disorder within a specific population at a given point in time or over a defined period. It includes both newly identified and previously diagnosed cases.



LA Kelley Communications, Inc.
21 Sawmill Way, Georgetown, MA 01833

You are receiving this email because you signed up for information from LA Kelley Communications, Inc. updates. If you no longer wish to receive these emails, you can [unsubscribe here](#).

[View as a Web Page](#)